Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014
Open Access
- 7 April 2020
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 20 (1), 1-10
- https://doi.org/10.1186/s12879-020-04981-0
Abstract
Background: The purpose of the study is to discuss the correlation between the resistance rate of gram negative bacteria to fluoroquinolones (FQ) and antibiotic consumption intensity of 145 China tertiary hospitals in 2014. Methods: This retrospective study adopted national monitoring data from 2014. Each participating hospital required to report annual consumption of each antibiotic, and the resistance rate of gram negative bacteria to FQ. Then the correlation between antibiotic usage and fluoroquinolones –resistant (FQR) rate was consequently investigated. Results: One hundred forty-five hospitals were included in the study, and the median antibiotic consumption intensity was 46.30 (23.93–115.39) defined daily dosages (DDDs) per 100 patient-days. Cephalosporins ranks first in the antibiotics consumption, followed by fluoroquinolones, penicillins, and carbapenems. Fluoroquinolones resistance rate varied from hospital to hospital. The correlation analysis showed significant relationship between the percentage of FQR Escherichia coli and the consumption of FQs (r = 0.308, ppKlebsiella pneumoniae, not only FQs (r = 0.291, pppPseudomonas aeruginosa was observed to be correlated with the consumption of all antibiotics (r = 0.260, ppAcinetobacter baumannii was significantly correlated with the consumption of all antibiotics (r = 0.282, pppA. baumannii and the antibiotics consumption was not found. Conclusions: A strong correlation was demonstrated between the antibiotic consumption and the rates of FQR gram-negative bacteria. As unreasonable antibiotics usage remains crucial in the proceeding of resistant bacteria selection, our study could greatly promote the avoidance of unnecessary antibiotic usage.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81711530049, 81361138021, 81800594)
- Key Research and Development Program of Zhejiang Province (2015C03032)
This publication has 48 references indexed in Scilit:
- Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coliJournal of Microbiology, Immunology and Infection, 2016
- Temporal Interplay between Efflux Pumps and Target Mutations in Development of Antibiotic Resistance in Escherichia coliAntimicrobial Agents and Chemotherapy, 2012
- Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitalsJournal of Antimicrobial Chemotherapy, 2012
- Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year studyJournal of Antimicrobial Chemotherapy, 2012
- The clinical impact of fluoroquinolone resistance in patients with E coli bacteremiaJournal of Hospital Medicine, 2011
- Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospitalJournal of Antimicrobial Chemotherapy, 2010
- Surveillance and Correlation of Antibiotic Prescription and Resistance of Gram-Negative Bacteria in Singaporean HospitalsAntimicrobial Agents and Chemotherapy, 2010
- Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006
- Practical Handbook for Healthcare Epidemiologists, 2nd Edition:Practical Handbook for Healthcare Epidemiologists, 2nd EditionClinical Infectious Diseases, 2005
- The Magnitude of the Association between Fluoroquinolone Use and Quinolone-Resistant Escherichia coli and Klebsiella pneumoniae May Be Lower than Previously ReportedAntimicrobial Agents and Chemotherapy, 2004